Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV
By:
References
- R. Loomba, S. L. Friedman and G. I. Shulman, Mechanisms and disease consequences of nonalcoholic fatty liver disease, <em>Cell</em> <bold>184</bold>(10) (2021) 2537–2564; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.cell.2021.04.015" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.cell.2021.04.015</a>">https://doi.org/10.1016/j.cell.2021.04.015</ext-link>
- F. Bessone, M. V. Razori and M. G. Roma, Molecular pathways of nonalcoholic fatty liver disease development and progression, <em>Cell. Mol. Life Sci.</em> <bold>76</bold>(1) (2019) 99–128; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s00018-018-2942-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s00018-018-2942-5</a>">https://doi.org/10.1007/s00018-018-2942-5</ext-link>
- M. Papatheodoridi and E. Cholongitas, Diagnosis of non-alcoholic fatty liver disease (NAFLD): Current concepts, <em>Curr. Pharm. Des.</em> <bold>24</bold>(38) (2018) 4574–4586; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.2174/1381612824666181002105543" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.2174/1381612824666181002105543</a>">https://doi.org/10.2174/1381612824666181002105543</ext-link>
- C. D. Byrne and G. Targher, NAFLD: A multisystem disease, <em>J. Hepatol.</em> <bold>62</bold>(1)(Suppl.) (2015) S47–S64; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2014.12.012" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2014.12.012</a>">https://doi.org/10.1016/j.jhep.2014.12.012</ext-link>
- A. Vadarlis, C. Antza, D. R. Bakaloudi, I. Doundoulakis, G. Kalopitas, M. Samara, T. Dardavessis, T. Maris and M. Chourdakis, Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease, <em>J. Gastroenterol. Hepatol.</em> <bold>36</bold>(2) (2021) 311–319; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/jgh.15221" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/jgh.15221</a>">https://doi.org/10.1111/jgh.15221</ext-link>
- M. Y. Wang, K. Prabahar, M. A. Găman and J. L. Zhang, Vitamin E supplementation in the treatment of nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials, <em>J. Dig. Dis.</em> <bold>24</bold>(6–7) (2023) 380–389; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/1751-2980.13210" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/1751-2980.13210</a>">https://doi.org/10.1111/1751-2980.13210</ext-link>
- C. Gofton, Y. Upendran, M. H. Zheng and J. George, MAFLD: How is it different from NAFLD?, <em>Clin. Mol. Hepatol.</em> <bold>29</bold>(Suppl) (2023) S17–S31; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3350/cmh.2022.0367" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3350/cmh.2022.0367</a>">https://doi.org/10.3350/cmh.2022.0367</ext-link>
- S. L. Friedman, B. A. Neuschwander-Tetri, M. Rinella and A. J. Sanyal, Mechanisms of NAFLD development and therapeutic strategies, <em>Nat. Med.</em> <bold>24</bold>(7) (2018) 908–922; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/s41591-018-0104-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/s41591-018-0104-9</a>">https://doi.org/10.1038/s41591-018-0104-9</ext-link>
- L. Rong, J. Zou, W. Ran, X. Qi, Y. Chen, H. Cui and J. Guo, Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD), <em>Front. Endocrinol.</em> (Lausanne) <bold>13</bold> (2023) Article ID 1087260 (18 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fendo.2022.1087260" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fendo.2022.1087260</a>">https://doi.org/10.3389/fendo.2022.1087260</ext-link>
- M. J. Watt, P. M. Miotto, W. De Nardo and M. K. Montgomery, The liver as an endocrine organ – Linking NAFLD and insulin resistance, <em>Endocr. Rev.</em> <bold>40</bold>(5) (2019) 1367–1393; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1210/er.2018-00241" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1210/er.2018-00241</a>">https://doi.org/10.1210/er.2018-00241</ext-link>
- Y. Sakurai, N. Kubota, T. Yamauchi and T. Kadowaki, Role of insulin resistance in MAFLD, <em>Int. J. Mol. Sci.</em> <bold>22</bold>(8) (2021) Article ID 4156 (26 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/ijms22084156" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/ijms22084156</a>">https://doi.org/10.3390/ijms22084156</ext-link>
- G. Paradies, V. Paradies, F. M. Ruggiero and G. Petrosillo, Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease, <em>World J. Gastroenterol.</em> <bold>20</bold>(39) (2014) 14205–14218; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3748/wjg.v20.i39.14205" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3748/wjg.v20.i39.14205</a>">https://doi.org/10.3748/wjg.v20.i39.14205</ext-link>
- J. Yang, M. Fernández-Galilea, L. Martínez-Fernández, P. González-Muniesa, A. Pérez-Chávez, J. A. Martínez and M. J. Moreno-Aliaga, Oxidative stress and non-alcoholic fatty liver disease: Effects of omega-3 fatty acid supplementation, <em>Nutrients</em> <bold>11</bold>(4) (2019) Article ID 872 (37 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/nu11040872" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/nu11040872</a>">https://doi.org/10.3390/nu11040872</ext-link>
- C. Luci, M. Bourinet, P. S. Leclère, R. Anty and P. Gual, Chronic inflammation in non-alcoholic steatohepatitis: Molecular mechanisms and therapeutic strategies, <em>Front. Endocrinol.</em> (Lausanne) <bold>11</bold> (2020) Article ID 597648 (14 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fendo.2020.597648" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fendo.2020.597648</a>">https://doi.org/10.3389/fendo.2020.597648</ext-link>
- R. Forlano, B. H. Mullish, S. K. Mukherjee, R. Nathwani, C. Harlow, P. Crook, R. Judge, A. Soubieres, P. Middleton, A. Daunt, P. Perez-Guzman, N. Selvapatt, M. Lemoine, A. Dhar, M. R. Thursz, S. Nayagam and P. Manousou, In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19, <em>PLoS One</em> <bold>15</bold>(10) (2020) e0240400; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1371/journal.pone.0240400" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1371/journal.pone.0240400</a>">https://doi.org/10.1371/journal.pone.0240400</ext-link>.
- A. A. Kolodziejczyk, D. Zheng, O. Shibolet and E. Elinav, The role of the microbiome in NAFLD and NASH, <em>EMBO Mol. Med.</em> <bold>11</bold>(2) (2019) e9302; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.15252/emmm.201809302" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.15252/emmm.201809302</a>">https://doi.org/10.15252/emmm.201809302</ext-link>
- A. Albillos, A. de Gottardi and M. Rescigno, The gut-liver axis in liver disease: Pathophysiological basis for therapy, <em>J. Hepatol.</em> <bold>72</bold>(3) (2020) 558–577; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2019.11.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2019.11.003</a>">https://doi.org/10.1016/j.jhep.2019.11.003</ext-link>
- Z. Younossi, Q. M. Anstee, M. Marietti, T. Hardy, L. Henry, M. Eslam, J. George and E. Bugianesi, Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention, <em>Nat. Rev. Gastroenterol. Hepatol.</em> <bold>15</bold>(1) (2018) 11–20; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/nrgastro.2017.109" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/nrgastro.2017.109</a>">https://doi.org/10.1038/nrgastro.2017.109</ext-link>
- S. Wei, L. Wang, P. C. Evans and S. Xu, NAFLD and NASH: Etiology, targets and emerging therapies, <em>Drug Discov. Today</em> <bold>29</bold>(3) (2024) Article ID 103910; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.drudis.2024.103910" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.drudis.2024.103910</a>">https://doi.org/10.1016/j.drudis.2024.103910</ext-link>
- Y. Sun, Y. Ma, F. Sun, W. Feng, H. Ye, T. Tian and M. Lei, Astragaloside IV attenuates lipopolysaccharide induced liver injury by modulating Nrf2-mediated oxidative stress and NLRP3-mediated inflammation, <em>Heliyon</em> <bold>9</bold>(4) (2023) e15436; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.heliyon.2023.e15436" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.heliyon.2023.e15436</a>">https://doi.org/10.1016/j.heliyon.2023.e15436</ext-link>
- S. Wu, F. Wen, X. Zhong, W. Du, M. Chen and J. Wang, Astragaloside IV ameliorate acute alcohol--induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway, <em>Ann. Med.</em> <bold>55</bold>(1) (2023) Article ID 2216942 (16 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1080/07853890.2023.2216942" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1080/07853890.2023.2216942</a>">https://doi.org/10.1080/07853890.2023.2216942</ext-link>
- Y. Li, X. Yang, X. Li, S. Wang, P. Chen, T. Ma and B. Zhang, Astragaloside IV and cycloastragenol promote liver regeneration through regulation of hepatic oxidative homeostasis and glucose/lipid metabolism, <em>Phytomedicine</em> <bold>135</bold> (2024) Article ID 156165; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.phymed.2024.156165" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.phymed.2024.156165</a>">https://doi.org/10.1016/j.phymed.2024.156165</ext-link>
- B. Zhou, D. L. Zhou, X. H. Wei, R. Y. Zhong, J. Xu and L. Sun, Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation, <em>Acta Pharmacol. Sin.</em> <bold>38</bold>(7) (2017) 998–1008; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/aps.2016.175" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/aps.2016.175</a>">https://doi.org/10.1038/aps.2016.175</ext-link>
- Y. Zhai, W. Zhou, X. Yan, Y. Qiao, L. Guan, Z. Zhang, H. Liu, J. Jiang, J. Liu and L. Peng, Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling, <em>Phytomedicine</em> <bold>107</bold> (2022) Article ID 154444; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.phymed.2022.154444" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.phymed.2022.154444</a>">https://doi.org/10.1016/j.phymed.2022.154444</ext-link>
- Y.-L. Liu, Q.-Z. Zhang, Y.-R. Wang, L.-N. Fu, J.-S. Han, J. Zhang and B.-M. Wang, Astragaloside IV improves high-fat diet-induced hepatic steatosis in nonalcoholic fatty liver disease rats by regulating inflammatory factors level via TLR4/NF-κB signaling pathway, <em>Front. Pharmacol.</em> <bold>11</bold> (2021) Article ID 605064 (11 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fphar.2020.605064" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fphar.2020.605064</a>">https://doi.org/10.3389/fphar.2020.605064</ext-link>
- J. M. Clark, Weight loss as a treatment for nonalcoholic fatty liver disease, <em>J. Clin. Gastroenterol.</em> <bold>40</bold>(Suppl. 1) (2006) S39–S43; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1097/01.mcg.0000168641.31321.fa" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1097/01.mcg.0000168641.31321.fa</a>">https://doi.org/10.1097/01.mcg.0000168641.31321.fa</ext-link>
- N. Hossain, P. Kanwar and S. R. Mohanty, A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD, <em>Gastroenterol. Res. Pract.</em> <bold>2016</bold> (2016) Article ID 7109270 (17 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1155/2016/7109270" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1155/2016/7109270</a>">https://doi.org/10.1155/2016/7109270</ext-link>
- S. Pouwels, N. Sakran, Y. Graham, A. Leal, T. Pintar, W. Yang, R. Kassir, R. Singhal, K. Mahawar and D. Ramnarain, Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss, <em>BMC Endocr. Disord</em>. <bold>22</bold>(1) (2022) Article ID 63 (9 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1186/s12902-022-00980-1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1186/s12902-022-00980-1</a>">https://doi.org/10.1186/s12902-022-00980-1</ext-link>
- M. F. Abdelmalek, Nonalcoholic fatty liver disease: Another leap forward, <em>Nat. Rev. Gastroenterol. Hepatol.</em> <bold>18</bold>(2) (2021) 85–86; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/s41575-020-00406-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/s41575-020-00406-0</a>">https://doi.org/10.1038/s41575-020-00406-0</ext-link>
- G. Farrell, Insulin resistance, obesity, and liver cancer, <em>Clin. Gastroenterol. Hepatol.</em> <bold>12</bold>(1) (2014) 117–119; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.cgh.2013.07.040" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.cgh.2013.07.040</a>">https://doi.org/10.1016/j.cgh.2013.07.040</ext-link>
- N. Sodum, G. Kumar, S. L. Bojja, N. Kumar and C. M. Rao, Epigenetics in NAFLD/NASH: Targets and therapy, <em>Pharmacol. Res.</em> <bold>167</bold> (2021) Article ID 105484; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.phrs.2021.105484" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.phrs.2021.105484</a>">https://doi.org/10.1016/j.phrs.2021.105484</ext-link>
- S. A. Harrison, A. M. Allen, J. Dubourg, M. Noureddin and N. Alkhouri, Challenges and opportunities in NASH drug development, <em>Nat. Med</em>. <bold>29</bold>(3) (2023) 562–573; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/s41591-023-02242-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/s41591-023-02242-6</a>">https://doi.org/10.1038/s41591-023-02242-6</ext-link>
- S. J. Song, J. C. T. Lai, G. L. H. Wong, V. W. S. Wong and T. C. F. Yip, Can we use old NAFLD data under the new MASLD definition?, <em>J. Hepatol.</em> <bold>80</bold>(2) (2024) e54–e56; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2023.07.021" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2023.07.021</a>">https://doi.org/10.1016/j.jhep.2023.07.021</ext-link>
- R. Younes and E. Bugianesi, The impact of metabolic syndrome on the outcome of NASH: Cirrhosis, hepatocellular carcinoma, and mortality, <em>Curr. Hepatol. Rep.</em> <bold>17</bold>(4) (2018) 336–344; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s11901-018-0422-x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s11901-018-0422-x</a>">https://doi.org/10.1007/s11901-018-0422-x</ext-link>
- T. Puengel and F. Tacke, Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH), <em>Expert Opin. Investig. Drugs</em> <bold>32</bold>(6) (2023) 451–461; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1080/13543784.2023.2230115" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1080/13543784.2023.2230115</a>">https://doi.org/10.1080/13543784.2023.2230115</ext-link>
- K. Shree Harini and D. Ezhilarasan, Wnt/β-catenin signaling and its modulators in nonalcoholic fatty liver diseases, <em>Hepatobiliary Pancreat. Dis. Int.</em> <bold>22</bold>(4) (2023) 333–345; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.hbpd.2022.10.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.hbpd.2022.10.003</a>">https://doi.org/10.1016/j.hbpd.2022.10.003</ext-link>
- N. Bhala, R. Younes and E. Bugianesi, Epidemiology and natural history of patients with NAFLD, <em>Curr. Pharm. Des.</em> <bold>19</bold>(29) (2013) 5169–5176; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.2174/13816128113199990336" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.2174/13816128113199990336</a>">https://doi.org/10.2174/13816128113199990336</ext-link>
- H. Kojima, S. Sakurai, M. Uemura, H. Fukui, H. Morimoto and Y. Tamagawa, Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis, <em>Alcohol Clin. Exp. Res.</em> <bold>31</bold>(s1) (2007) S61–S66; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/j.1530-0277.2006.00288.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/j.1530-0277.2006.00288.x</a>">https://doi.org/10.1111/j.1530-0277.2006.00288.x</ext-link>
- N. Alkhouri, M. P. Berk, R. Lopez, T. Abu-Rajab Tamimi, L. Yerian, Y. Chung, R. Zhang, T. M. Mc-Intyre, S. L. Hazen and A. E. Feldstein, OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease, <em>Dig. Dis. Sci.</em> <bold>59</bold>(7) (2014) 1617–1624; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s10620-014-3031-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s10620-014-3031-8</a>">https://doi.org/10.1007/s10620-014-3031-8</ext-link>
- L. S. R. R. Okada, C. P. Oliveira, J. T. Stefano, M. A. Nogueira, I. D. C. G. da Silva, F. B. Cordeiro, V. A. F. Alves, R. S. Torrinhas, F. J. Carrilho, P. Puri and D. L. Waitzberg, Omega-3 PUFA modulate lipo-genesis, ER stress, and mitochondrial dysfunction markers in NASH – proteomic and lipidomic insight, <em>Clin. Nutr.</em> <bold>37</bold>(5) (2017) 1474–1484; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.clnu.2017.08.031" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.clnu.2017.08.031</a>">https://doi.org/10.1016/j.clnu.2017.08.031</ext-link>
- J. S. Chang, J. H. Ahn, S. H. Kang, S. B. Koh, J. Y. Kim, S. K. Baik, J. H. Huh, S. S. Lee, M. Y. Kim and K. S. Park, Metabolic stress index including mitochondrial biomarker for noninvasive diagnosis of hepatic steatosis, <em>Front. Endocrinol.</em> <bold>13</bold> (2022) Article ID 896334 (8 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fendo.2022.896334" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fendo.2022.896334</a>">https://doi.org/10.3389/fendo.2022.896334</ext-link>
- S. Seki, T. Kitada and H. Sakaguchi, Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases, <em>Hepatol. Res.</em> <bold>33</bold>(2) (2005) 132–134; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.hepres.2005.09.020" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.hepres.2005.09.020</a>">https://doi.org/10.1016/j.hepres.2005.09.020</ext-link>
- J. Zhang, C. Wu, L. Gao, G. Du and X. Qin, Astragaloside IV derived from <em>Astragalus membranaceus</em>: A research review on the pharmacological effects, <em>Adv. Pharmacol.</em> <bold>87</bold> (2020) 89–112; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/bs.apha.2019.08.002" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/bs.apha.2019.08.002</a>">https://doi.org/10.1016/bs.apha.2019.08.002</ext-link>
- L. Li, X. Hou, R. Xu, C. Liu and M. Tu, Research review on the pharmacological effects of astragalo-side IV, <em>Fundam. Clin. Pharmacol.</em> <bold>31</bold>(1) (2017) 17–36; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/fcp.12232" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/fcp.12232</a>">https://doi.org/10.1111/fcp.12232</ext-link>
- Z. Zhuang, Z.-H. Wang, L.-H. Deng, Q. Zheng, G.-Q. Zheng and Y. Wang, Astragaloside IV exerts cardioprotection in animal models of viral myocarditis: A preclinical systematic review and meta-analysis, <em>Front. Pharmacol.</em> <bold>10</bold> (2019) Article ID 1388 (11 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fphar.2019.01388" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fphar.2019.01388</a>">https://doi.org/10.3389/fphar.2019.01388</ext-link>
- F. Xu, W. Q. Cui, Y. Wei, J. Cui, J. Qiu, L. L. Hu, W. Y. Gong, J. C. Dong and B. J. Liu, Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling, <em>J. Exp. Clin. Cancer Res.</em> <bold>37</bold>(1) (2018) Article ID 207 (16 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1186/s13046-018-0878-0" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1186/s13046-018-0878-0</a>">https://doi.org/10.1186/s13046-018-0878-0</ext-link>
- Z. Han, J. Zhu and Z. Han, Evaluation of astragaloside IV in hepatic fibrosis: A meta-analysis, <em>Medicine</em> <bold>100</bold>(13) (2021) e25105; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1097/MD.0000000000025105" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1097/MD.0000000000025105</a>">https://doi.org/10.1097/MD.0000000000025105</ext-link>
- H. Wang, Z. Zhuang, Y.-Y. Huang, Y. Zhuang, J. Jin, X. Ye, Z. Lin, J. Zheng and H. Wang, Protective effect and possible mechanisms of astragaloside IV in animal models of diabetic nephropathy: A preclinical systematic review and meta-analysis, <em>Front. Pharmacol.</em> <bold>11</bold> (2020) Article ID 988 (17 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fphar.2020.00988" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fphar.2020.00988</a>">https://doi.org/10.3389/fphar.2020.00988</ext-link>
- I. M. Costa, F. O. V. Lima, L. C. B. Fernandes, B. Norrara, F. I. Neta, R. D. Alves, J. R. L. P. Cavalcanti, E. E. S. Lucena, J. S. Cavalcante, A. C. M. Rego, I. A. Filho, D. B. Queiroz, M. A. M. Freire and F. P. Guzen, Astragaloside IV supplementation promotes a neuroprotective effect in experimental models of neurological disorders: A systematic review, <em>Curr. Neuropharmacol.</em> <bold>17</bold>(7) (2019) 648–665; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.2174/1570159X16666180911123341" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.2174/1570159X16666180911123341</a>">https://doi.org/10.2174/1570159X16666180911123341</ext-link>
- M. Marušić, M. Paić, M. Knobloch and A.-M. Liberati Pršo, NAFLD, insulin resistance, and diabetes mellitus type 2, <em>Can. J. Gastroenterol. Hepatol.</em> <bold>2021</bold> (2021) Article ID 6613827 (9 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1155/2021/6613827" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1155/2021/6613827</a>">https://doi.org/10.1155/2021/6613827</ext-link>
- D. Xia, W. Li, C. Tang and J. Jiang, Astragaloside IV, as a potential anticancer agent, <em>Front. Pharmacol.</em> <bold>14</bold> (2023) Article ID 1065505 (15 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fphar.2023.1065505" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fphar.2023.1065505</a>">https://doi.org/10.3389/fphar.2023.1065505</ext-link>
- K. Mehta, D. H. Van Thiel, N. Shah and S. Mobarhan, Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants, <em>Nutr. Rev.</em> <bold>60</bold>(9) (2002) 289–293; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1301/002966402320387224" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1301/002966402320387224</a>">https://doi.org/10.1301/002966402320387224</ext-link>
- F. Item, S. Wueest, V. Lemos, S. Stein, F. C. Lucchini, R. Denzler, M. C. Fisser, T. D. Challa, E. Pirinen, Y. Kim, S. Hemmi, E. Gulbins, A. Gross, L. A. O’Reilly, M. Stoffel, J. Auwerx and D. Konrad, Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function, <em>Nat. Commun</em>. <bold>8</bold>(1) (2017) Article ID 480 (10 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/s41467-017-00566-9" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/s41467-017-00566-9</a>">https://doi.org/10.1038/s41467-017-00566-9</ext-link>
- L. Ding, W. Sun, M. Balaz, A. He, M. Klug, S. Wieland, R. Caiazzo, V. Raverdy, F. Pattou, P. Lefebvre, I. J. Lodhi, B. Staels, M. Heim and C. Wolfrum, Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis, <em>Nat. Metab.</em> <bold>3</bold>(12) (2021) 1648–1661; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/s42255-021-00489-2" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/s42255-021-00489-2</a>">https://doi.org/10.1038/s42255-021-00489-2</ext-link>
- X. Zhou, L. L. Wang, W. J. Tang and B. Tang, Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells, <em>J. Ethnopharmacol</em>. <bold>268</bold>(11) (2021) Article ID 113556; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jep.2020.113556" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jep.2020.113556</a>">https://doi.org/10.1016/j.jep.2020.113556</ext-link>
- J. L. Rains and S. K. Jain, Oxidative stress, insulin signaling, and diabetes, <em>Free Radic. Biol. Med.</em> <bold>50</bold>(5) (2011) 567–575; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.freeradbiomed.2010.12.006" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.freeradbiomed.2010.12.006</a>">https://doi.org/10.1016/j.freeradbiomed.2010.12.006</ext-link>
- S. Vomund, A. Schäfer, M. J. Parnham, B. Brüne and A. Von Knethen, Nrf2, the master regulator of anti-oxidative responses, <em>Int. J. Mol. Sci.</em> <bold>18</bold>(12) (2017) Article ID 2772 (19 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/ijms18122772" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/ijms18122772</a>">https://doi.org/10.3390/ijms18122772</ext-link>
- S. Herzig and R. J. Shaw, AMPK: Guardian of metabolism and mitochondrial homeostasis, <em>Nat. Rev. Mol. Cell Biol.</em> <bold>19</bold>(2) (2018) 121–135; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/nrm.2017.95" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/nrm.2017.95</a>">https://doi.org/10.1038/nrm.2017.95</ext-link>
- H. Yun, S. Park, M. J. Kim, W. K. Yang, D. U. Im, K. R. Yang, J. Hong, W. Choe, I. Kang, S. S. Kim and J. Ha, AMP-activated protein kinase mediates the antioxidant effects of resveratrol through regulation of the transcription factor FoxO1, <em>FEBS J.</em> <bold>281</bold>(19) (2014) 4421–4438; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/febs.12949" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/febs.12949</a>">https://doi.org/10.1111/febs.12949</ext-link>
- Q. Lu, L. Yang, J.-J. Xiao, Q. Liu, L. Ni, J.-W. Hu, H. Yu, X. Wu and B.-F. Zhang, Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway, <em>Free Radic. Biol. Med.</em> <bold>195</bold> (2023) 89–102; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.freeradbiomed.2022.12.088" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.freeradbiomed.2022.12.088</a>">https://doi.org/10.1016/j.freeradbiomed.2022.12.088</ext-link>
- X. Li, D. Wu and T. Ye, Fibroblast growth factor 19 protects the heart from oxidative stress-induced diabetic cardiomyopathy via activation of AMPK/Nrf2/HO-1 pathway, <em>Biochem. Biophys. Res. Commun.</em> <bold>502</bold>(1) (2018) 62–68; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.bbrc.2018.05.121" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.bbrc.2018.05.121</a>">https://doi.org/10.1016/j.bbrc.2018.05.121</ext-link>
- X. H. Zhou, L. Q. He, S. N. Zuo, Y. M. Zhang, D. Wan, C. M. Long, P. Huang, X. Wu, C. R. Wu, G. Liu and Y. Yin, Serine prevented high-fat diet–induced oxidative stress by activating AMPK and epigenetically modulating the expression of glutathione synthesis-related genes, <em>Biochim. Biophys. Acta Mol. Basis Dis.</em> <bold>1864</bold>(2) (2018) 488–498; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.bbadis.2017.11.009" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.bbadis.2017.11.009</a>">https://doi.org/10.1016/j.bbadis.2017.11.009</ext-link>
- L. Li, W. X. Huang, S. K. Wang, K. Sun, W. Zhang, Y. Ding, L. Zhang, B. Tumen and L. Lang, Astragaloside IV attenuates acetaminophen-induced liver injuries in mice by activating the Nrf2 signaling pathway, <em>Molecules</em> <bold>23</bold>(8) (2018) Article ID 2032 (9 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/molecules23082032" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/molecules23082032</a>">https://doi.org/10.3390/molecules23082032</ext-link>
- N. Cheng, S. Chen, X. Liu, H. Zhao and W. Cao, Impact of <em>Schisandra chinensis</em> bee pollen on non-alcoholic fatty liver disease and gut microbiota in high-fat diet induced obese mice, <em>Nutrients</em> <bold>11</bold>(2) (2019) Article ID 346 (16 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/nu11020346" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/nu11020346</a>">https://doi.org/10.3390/nu11020346</ext-link>
- M. Martin, K. Rehani, R. S. Jope and S. M. Michalek, Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3, <em>Nat. Immunol.</em> <bold>6</bold>(8) (2005) 777–784; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/ni1221" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/ni1221</a>">https://doi.org/10.1038/ni1221</ext-link>
- D. Sag, D. Carling, R. D. Stout and J. Suttles, Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype, <em>J. Immunol.</em> <bold>181</bold>(12) (2008) 8633–8641; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.4049/jimmunol.181.12.8633" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.4049/jimmunol.181.12.8633</a>">https://doi.org/10.4049/jimmunol.181.12.8633</ext-link>
- R. Wei, H. Liu, R. Chen, Y. Sheng and T. Liu, Astragaloside IV combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway, <em>Exp. Ther. Med.</em> <bold>17</bold>(1) (2019) 393–397; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3892/etm.2018.6966" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3892/etm.2018.6966</a>">https://doi.org/10.3892/etm.2018.6966</ext-link> Spandidos Publications
- D. Qin, D. N. Ma, Z. G. Ren, X. D. Zhu, C. H. Wang, Y. C. Wang, B. Ye, M. Cao, D. Gao, Z. Tang and Z. Tang, Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway, <em>Oncol. Rep.</em> <bold>37</bold>(3) (2017) 1725–1735; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3892/or.2017.5389" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3892/or.2017.5389</a>">https://doi.org/10.3892/or.2017.5389</ext-link>
- X. Qu, H. Gao, L. Tao, Y. Zhang, J. Zhai, J. Sun, Y. Song and S. Zhang, Astragaloside IV protects against cisplatin-induced liver and kidney injury via autophagy-mediated inhibition of NLRP3 in rats, <em>J. Toxicol. Sci.</em> <bold>44</bold>(3) (2019) 167–175; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.2131/jts.44.167" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.2131/jts.44.167</a>">https://doi.org/10.2131/jts.44.167</ext-link>
- J. R. Ham, H.-I. Lee, R.-Y. Choi, M.-O. Sim, K.-I. Seo and M.-K. Lee, Anti-steatotic and anti-inflammatory roles of syringic acid in high-fat diet-induced obese mice, <em>Food Funct.</em> <bold>7</bold>(2) (2016) 689–697; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1039/C5FO01411A" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1039/C5FO01411A</a>">https://doi.org/10.1039/C5FO01411A</ext-link>
- G. Baffy, Kupffer cells in non-alcoholic fatty liver disease: The emerging view, <em>J. Hepatol.</em> <bold>51</bold>(1) (2009) 212–223; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2009.03.008" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2009.03.008</a>">https://doi.org/10.1016/j.jhep.2009.03.008</ext-link>
- S. Saravanan, V. I. Islam, N. P. Babu, P. Pandikumar, K. Thirugnanasambantham, M. Chellappandian, C. S. Raj, M. G. Paulraj and S. Ignacimuthu, Swertiamarin attenuates inflammation mediators via modulating NF-κB/IκB and JAK2/STAT3 transcription factors in adjuvant induced arthritis, <em>Eur. J. Pharm. Sci.</em> <bold>56</bold> (2014) 70–86; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.ejps.2014.02.005" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.ejps.2014.02.005</a>">https://doi.org/10.1016/j.ejps.2014.02.005</ext-link>
- Z. L. Bian, Y. Peng, Z. You, Q. Wang, Q. Miao, Y. Liu, X. Han, D. Qiu, Z. Li and X. Ma, CCN1 expression in hepatocytes contributes to macrophage infiltration in nonalcoholic fatty liver disease in mice, <em>J. Lipid Res.</em> <bold>54</bold>(1) (2013) 44–54; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1194/jlr.M026013" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1194/jlr.M026013</a>">https://doi.org/10.1194/jlr.M026013</ext-link>
- E. Radi, P. Formichi, C. Battisti and A. Federico, Apoptosis and oxidative stress in neurodegenerative diseases, <em>J. Alzheimer’s Dis.</em> <bold>42</bold>(Suppl. 3) (2014) S125–S152; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3233/JAD-132738" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3233/JAD-132738</a>">https://doi.org/10.3233/JAD-132738</ext-link>
- K. J. Campbell and S. W. G. Tait, Targeting BCL-2 regulated apoptosis in cancer, <em>Open Biol</em>. <bold>8</bold>(5) (2018) Article ID 180002 (11 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1098/rsob.180002" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1098/rsob.180002</a>">https://doi.org/10.1098/rsob.180002</ext-link>
- C. A. Gregory, H. Singh, A. S. Perry and D. J. Prockop, Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion, <em>J. Biol. Chem.</em> <bold>278</bold>(22) (2003) 19732–19742; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1074/jbc.M300373200" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1074/jbc.M300373200</a>">https://doi.org/10.1074/jbc.M300373200</ext-link>
- C. Cárdenas, R. A. Miller, I. Smith, T. Bui, J. Molgó, M. Müller, H. Vais, K.-H. Cheung, J. Yang, I. Parker, C. B. Thompson, M. J. Birnbaum, K. R. Hallows and J. K. Foskett, Essential regulation of cell bioenergetics by constitutive InsP₃ receptor Ca²⁺ transfer to mitochondria, <em>Cell</em> <bold>142</bold>(2) (2010) 270–283; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.cell.2010.06.007" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.cell.2010.06.007</a>">https://doi.org/10.1016/j.cell.2010.06.007</ext-link>
- J. A. Martinez, Z. Zhang, S. I. Svetlov, R. L. Hayes, K. K. Wang and S. F. Larner, Calpain and caspase processing of caspase-12 contribute to the ER stress-induced cell death pathway in differentiated PC12 cells, <em>Apoptosis</em> <bold>15</bold>(12) (2010) 1480–1493; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s10495-010-0531-7" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s10495-010-0531-7</a>">https://doi.org/10.1007/s10495-010-0531-7</ext-link>
- C. J. Hanson, M. D. Bootman, C. W. Distelhorst, R. J. H. Wojcikiewicz and H. L. Roderick, Bcl-2 suppresses Ca²⁺ release through inositol 1,4,5-trisphosphate receptors and inhibits Ca²⁺ uptake by mitochondria without affecting ER calcium store content, <em>Cell Calcium</em> <bold>44</bold>(3) (2008) 324–338; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.ceca.2008.01.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.ceca.2008.01.003</a>">https://doi.org/10.1016/j.ceca.2008.01.003</ext-link>
- X.-Y. Liang, F.-F. Hong and S.-L. Yang, Astragaloside IV alleviates liver inflammation, oxidative stress and apoptosis to protect against experimental non-alcoholic fatty liver disease, <em>Diabetes Metab. Syndr. Obes.</em> <bold>14</bold> (2021) 1871–1883; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.2147/DMSO.S304817" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.2147/DMSO.S304817</a>">https://doi.org/10.2147/DMSO.S304817</ext-link>
- X. Liu, W. Chu, S. Shang, L. Ma, C. Jiang, Y. Ding, J. Wang, S. Zhang and B. Shao, Preliminary study on the anti-apoptotic mechanism of astragaloside IV on radiation-induced brain cells, <em>Int. J. Immunopathol. Pharmacol</em>. <bold>34</bold> (2020) Article ID 2058738420954594; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1177/2058738420954594" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1177/2058738420954594</a>">https://doi.org/10.1177/2058738420954594</ext-link>
- Z. Liu, Z. Zhou, P. Ai, C. Zhang, J. Chen and Y. Wang, Astragaloside IV attenuates ferroptosis after subarachnoid hemorrhage via Nrf2/HO-1 signaling pathway, <em>Front. Pharmacol.</em> <bold>13</bold> (2022) Article ID 924826 (13 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fphar.2022.924826" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fphar.2022.924826</a>">https://doi.org/10.3389/fphar.2022.924826</ext-link>
- Z. Qi, P. Zhang, L. Yang, P. Song, J. Zhao, H. Wang, Y. Zhao and L. Cao, Astragaloside IV alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte pyroptosis through the SIRT1/NLRP3 pathway, <em>Am. J. Chin. Med.</em> <bold>52</bold>(2) (2024) 453–469; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1142/S0192415X24500198" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1142/S0192415X24500198</a>">https://doi.org/10.1142/S0192415X24500198</ext-link>
- X. Meng, G. Zhang, H. Cao, D. Yu, X. Fang, W. M. de Vos and H. Wu, Gut dysbacteriosis and intestinal disease: Mechanism and treatment, <em>J. Appl. Microbiol</em>. <bold>129</bold>(4) (2020) 787–805; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/jam.14661" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/jam.14661</a>">https://doi.org/10.1111/jam.14661</ext-link>
- L. L. Deng, Astragaloside IV as potential antioxidant against diabetic ketoacidosis in juvenile mice through activating JNK/Nrf2 signaling pathway, <em>Arch. Med. Res.</em> <bold>51</bold>(7) (2020) 654–663; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.arcmed.2020.06.013" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.arcmed.2020.06.013</a>">https://doi.org/10.1016/j.arcmed.2020.06.013</ext-link>
- D. M. Chopyk and A. Grakoui, Contribution of the intestinal microbiome and gut barrier to hepatic disorders, <em>Gastroenterology</em> <bold>159</bold>(3) (2020) 849–863; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1053/j.gastro.2020.04.077" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1053/j.gastro.2020.04.077</a>">https://doi.org/10.1053/j.gastro.2020.04.077</ext-link>
- J. W. Jung, F. Wang, A. Turk, J. S. Park, H. Ma, Y. Ma, H.-R. Noh, G. Sui, D. S. Shin, M. K. Lee and Y. S. Roh, Zaluzanin C alleviates inflammation and lipid accumulation in Kupffer cells and hepatocytes by regulating mitochondrial ROS, <em>Molecules</em> <bold>28</bold>(22) (2023) Article ID 7484; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/molecules28227484" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/molecules28227484</a>">https://doi.org/10.3390/molecules28227484</ext-link>
- J. Fang, C.-H. Yu, X.-J. Li, J.-M. Yao, Z.-Y. Fang, S.-H. Yoon and W.-Y. Yu, Gut dysbiosis in nonalcoholic fatty liver disease: Pathogenesis, diagnosis, and therapeutic implications, <em>Front. Cell. Infect. Microbiol.</em> <bold>12</bold> (2022) Article ID 997018 (12 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fcimb.2022.997018" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fcimb.2022.997018</a>">https://doi.org/10.3389/fcimb.2022.997018</ext-link>
- D. Zhang, X. Hao, L. Xu, J. Cui, L. Xue and Z. Tian, Intestinal flora imbalance promotes alcohol-induced liver fibrosis by the TGFβ/Smad signaling pathway in mice, <em>Oncol. Lett.</em> <bold>14</bold>(4) (2017) 4511–4516; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3892/ol.2017.6762" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3892/ol.2017.6762</a>">https://doi.org/10.3892/ol.2017.6762</ext-link>
- A. Wieland, D. N. Frank, B. Harnke and K. Bambha, Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease, <em>Aliment. Pharmacol. Ther.</em> <bold>42</bold>(9) (2015) 1051–1063; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/apt.13376" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/apt.13376</a>">https://doi.org/10.1111/apt.13376</ext-link>
- L. Xue, Z. Deng, W. Luo, X. He and Y. Chen, Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial, <em>Front. Cell. Infect. Microbiol.</em> <bold>12</bold> (2022) Article ID 759306 (10 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fcimb.2022.759306" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fcimb.2022.759306</a>">https://doi.org/10.3389/fcimb.2022.759306</ext-link>
- V. Kaden-Volynets, M. Basic, U. Neumann, D. Pretz, A. Rings, A. Bleich and S. C. Bischoff, Lack of liver steatosis in germ-free mice following hypercaloric diets, <em>Eur. J. Nutr.</em> <bold>58</bold> (2019) 1933–1945; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1007/s00394-018-1748-4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1007/s00394-018-1748-4</a>">https://doi.org/10.1007/s00394-018-1748-4</ext-link>
- J. Fu, M. J. Bonder, M. C. Cenit, E. F. Tigchelaar, A. Maatman, J. A. M. Dekens, E. Brandsma, J. Marczynska, F. Imhann, R. K. Weersma, L. Franke, T. W. Poon, R. J. Xavier, D. Gevers, M. H. Hofker, C. Wijmenga and A. Zhernakova, The gut microbiome contributes to a substantial proportion of the variation in blood lipids, <em>Circ. Res</em>. <bold>117</bold>(9) (2015) 817–824; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1161/CIRCRESAHA.115.306807" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1161/CIRCRESAHA.115.306807</a>">https://doi.org/10.1161/CIRCRESAHA.115.306807</ext-link>
- Z. Li, E. Hu, F. Zheng, S. Wang, W. Zhang, J. Luo, T. Tang, Q. Huang and Y. Wang, The effects of astragaloside IV on gut microbiota and serum metabolism in a mice model of intracerebral hemorrhage, <em>Phytomedicine</em> <bold>121</bold> (2023) Article ID 155086; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.phymed.2023.155086" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.phymed.2023.155086</a>">https://doi.org/10.1016/j.phymed.2023.155086</ext-link>
- X. Q. Du, L. P. Shi, Z. W. Chen, J. Y. Hu, B. Zuo, Y. Xiong and W. F. Cao, Astragaloside IV ameliorates isoprenaline-induced cardiac fibrosis in mice via modulating gut microbiota and fecal metabolites, <em>Front. Cell. Infect. Microbiol.</em> <bold>12</bold> (2022) Article ID 836150 (11 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3389/fcimb.2022.836150" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3389/fcimb.2022.836150</a>">https://doi.org/10.3389/fcimb.2022.836150</ext-link>
- T. Yang, S. Xie, L. Cao, M. Li, L. Ding, L. Wang, S. Pang, Z. Wang and L. Geng, Astragaloside IV modulates gut macrophages M1/M2 polarization by reshaping gut microbiota and short chain fatty acids in sepsis, <em>Shock</em> <bold>61</bold>(1) (2024) 120–131; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1097/SHK.0000000000002262" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1097/SHK.0000000000002262</a>">https://doi.org/10.1097/SHK.0000000000002262</ext-link>
- P. Golabi, H. Bush, M. Stepanova, C. T. Locklear, J. P. Weston, Z. Goodman, I. M. Younossi and Z. M. Younossi, Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steato-hepatitis (NASH) cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016, <em>Medicine</em> <bold>97</bold>(31) (2018) e11518; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1097/MD.0000000000011518" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1097/MD.0000000000011518</a>">https://doi.org/10.1097/MD.0000000000011518</ext-link>
- S. A. Harrison, M. R. Bashir, C. D. Guy, R. Zhou, C. A. Moylan, J. P. Frias, N. Alkhouri, M. B. Bansal, S. Baum, B. A. Neuschwander-Tetri, R. Taub and S. E. Moussa, Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo- controlled, phase 2 trial, <em>Lancet</em> <bold>394</bold>(10213) (2019) 2012–2024; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S0140-6736(19)32517-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S0140-6736(19)32517-6</a>">https://doi.org/10.1016/S0140-6736(19)32517-6</ext-link>
- A. R. Saran, S. Dave and A. Zarrinpar, Circadian rhythms in the pathogenesis and treatment of fatty liver disease, <em>Gastroenterology</em> <bold>158</bold>(7) (2020) 1948–1966.e1; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1053/j.gastro.2020.01.050" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1053/j.gastro.2020.01.050</a>">https://doi.org/10.1053/j.gastro.2020.01.050</ext-link>
- S. M. Francque, P. Bedossa, V. Ratziu, Q. M. Anstee, E. Bugianesi, A. J. Sanyal, R. Loomba, S. A. Harrison, R. Balabanska, L. Mateva, N. Lanthier, N. Alkhouri, C. Moreno, J. M. Schattenberg, D. Stefanova-Petrova, L. Vonghia, R. Rouzier, M. Guillaume, A. Hodge, M. Romero-Gómez, P. Huot-Marchand, M. Baudin, M.-P. Richard, J.-L. Abitbol, P. Broqua, J.-L. Junien and M. F. Abdelmalek, A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH, <em>N. Engl. J. Med.</em> <bold>385</bold>(17) (2021) 1547–1558; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1056/NEJMoa2036205" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1056/NEJMoa2036205</a>">https://doi.org/10.1056/NEJMoa2036205</ext-link>
- P. N. Newsome, K. Buchholtz, K. Cusi, M. Linder, T. Okanoue, V. Ratziu, A. J. Sanyal, A.-S. Sejling and S. A. Harrison, A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steato-hepatitis, <em>N. Engl. J. Med.</em> <bold>384</bold>(12) (2021) 1113–1124; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1056/NEJMoa2028395" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1056/NEJMoa2028395</a>">https://doi.org/10.1056/NEJMoa2028395</ext-link>
- N. Alkhouri, R. Herring, H. Kabler, Z. Kayali, T. Hassanein, A. Kohli, R. S. Huss, Y. Zhu, A. N. Billin, L. H. Damgaard, K. Buchholtz, M. S. Kjær, C. Balendran, R. P. Myers, R. Loomba and M. Noureddin, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial, <em>J. Hepatol.</em> <bold>77</bold>(3) (2022) 607–618; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.jhep.2022.04.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.jhep.2022.04.003</a>">https://doi.org/10.1016/j.jhep.2022.04.003</ext-link>
- R. Loomba, E. J. Lawitz, J. P. Frias, G. Ortiz-Lasanta, L. Johansson, B. B. Franey, L. Morrow, M. Rosenstock, C. L. Hartsfield, C.-Y. Chen, L. Tseng, R. W. Charlton, H. Mansbach and M. Margalit, Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending--dose study, <em>Lancet Gastroenterol. Hepatol.</em> <bold>8</bold>(2) (2023) 120–132; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S2468-1253(22)00347-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S2468-1253(22)00347-8</a>">https://doi.org/10.1016/S2468-1253(22)00347-8</ext-link>
- S. A. Harrison, J. P. Frias, G. Neff, G. A. Abrams, K. J. Lucas, W. Sanchez, S. Gogia, M. Y. Sheikh, C. Behling, P. Bedossa, L. Shao, D. Chan, E. Fong, B. de Temple, R. Shringarpure, E. J. Tillman, T. Rolph, A. Cheng and K. Yale, Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo--controlled, phase 2b trial, <em>Lancet Gastroenterol. Hepatol.</em> <bold>8</bold>(12) (2023) 1080–1093; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/S2468-1253(23)00272-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/S2468-1253(23)00272-8</a>">https://doi.org/10.1016/S2468-1253(23)00272-8</ext-link>
- J. Zhou, L. R. Waskowicz, A. Lim, X.-H. Liao, B. Lian, H. Masamune, S. Refetoff, B. Tran, D. D. Koeberl and P. M. Yen, A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia, <em>Thyroid</em> <bold>29</bold>(8) (2019) 1158–1167; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1089/thy.2019.0007" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1089/thy.2019.0007</a>">https://doi.org/10.1089/thy.2019.0007</ext-link>
- S. A. Harrison, R. Taub, G. W. Neff, K. J. Lucas, D. Labriola, S. E. Moussa, N. Alkhouri and M. R. Bashir, Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial, <em>Nat. Med</em>. <bold>29</bold>(11) (2023) 2919–2928; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/s41591-023-02603-1" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/s41591-023-02603-1</a>">https://doi.org/10.1038/s41591-023-02603-1</ext-link>
- Chinese Pharmacopoeia Commission, <em>Pharmacopoeia of the People’s Republic of China</em>, 11th ed., China Medical Science Press, Beijing 2020.
Language: English
Accepted on: Jun 5, 2025
Published on: Jul 16, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2025 Hui Wang, Yunqin Jiang, Shiyun Wang, Chanchan Lu, Lumin Tang, Tingting Gu, Shi Shu, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.